查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球慢性淋巴细胞白血病药物市场-2022-2029
市场调查报告书
商品编码
1140692

全球慢性淋巴细胞白血病药物市场-2022-2029

Global Chronic Lymphocytic Leukemia Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），慢性淋巴细胞白血病治疗药物的市场规模预计将以 7.90% 的复合年增长率增长。

慢性淋巴细胞白血病 (CLL) 是一种以白细胞异常增殖为特征的血液系统恶性肿瘤。 CLL 主要影响 B 细胞淋巴细胞，后者负责产生抗体以对抗感染和外来抗原。慢性淋巴细胞白血病的症状包括淋巴结肿大、发热、消瘦、脾肿大引起的腹痛、体重减轻、盗汗和反復感染。

市场动态

FDA 越来越多地批准治疗慢性淋巴细胞白血病有望推动市场增长。

2020 年 4 月 21 日，美国食品药品监督管理局 (FDA) 宣布，与利妥昔单抗联合用于既往未经治疗的慢性淋巴细胞白血病 (CLL) 或小淋巴细胞淋巴瘤 (SLL) 患者的依鲁替尼 (ibrutinib) 获得批准。这标誌着 FDA 自 2013 年批准以来第 11 次批准 imbruvica (ibrutinib) 和第 6 次批准 CLL，CLL 是成人中最常见的白血病形式。此外，2020年11月9日，它被欧洲医疗机构（EMA）批准用于治疗成年慢性淋巴细胞白血病（CLL）患者。因此，从上述陈述来看，预计将在预测期内推动市场。

约束

严格的政府法规、新兴国家不适当的报销政策以及多个专利到期预计将阻碍市场增长。

行业分析

慢性淋巴细胞白血病治疗市场根据各种行业因素（包括未满足的需求、定价分析、供应链分析、监管分析和流行病学）对市场进行深入分析。

细分分析

预计靶向治疗部分将在慢性淋巴细胞白血病治疗市场中占据最大的市场份额。

2021 年，靶向治疗领域将占据最大的市场份额。靶向疗法是专门针对导致癌症的细胞变化的药物。与一般通过攻击快速生长的细胞（包括癌细胞）起作用的标准化疗药物不同，慢性淋巴细胞白血病（CLL）细胞上或内部的一种或多种药物的特点是靶向特定的蛋白质。当 CLL 需要治疗时，靶向治疗通常是第一线治疗的一部分。靶向治疗药物是精准医疗中高度适用的治疗方法，因为它们利用人类基因和蛋白质的信息来预防、诊断和治疗疾病。靶向药物主要用于治疗癌症，以及其他治疗方法，如化学疗法、手术和放射疗法。由于慢性淋巴细胞白血病 (CLL) 的发病率不断增加，靶向癌症治疗市场正在扩大。例如，根据美国癌症协会 2020 年 1 月发布的一份报告，CLL 的风险随着年龄的增长而增加，估计每 10 名 CLL 患者中约有 9 名年龄在 50 岁以上，这表明 CLL 市场正在增长。直接支持最常用于治疗 CLL 的靶向药物主要类别是利妥昔单抗 (Rituxan)、ofatumumab (Alzera)、obinutuzumab (Gazeeva)、venetoclax (Venclekta)、依鲁替尼 (Imbruvica) 和 idelalisib (Zydrig)。因此，对靶向治疗的需求越来越大。因此，根据上述描述，该细分市场在预测期内占最大的市场份额。

按地区分析

预计北美将占据全球慢性淋巴细胞白血病药物市场的最大市场份额。

2021 年，北美市场份额最大。 CLL 发病率的上升和高死亡率表明市场对更好的治疗药物的需求尚未得到满足。例如，根据 Cancer.net 的数据，到 2021 年，美国将有 21,250 名所有年龄段的人（13,040 名男性和 8,210 名女性和 8,210 名女性）被诊断出患有 CLL。虽然它可以发生在任何年龄，但 CLL 在老年人中更常见。诊断时的平均年龄约为 70 岁。 CLL 在 40 岁以下的人中很少见，在儿童中非常罕见。 CLL 是 19 岁以上成人中最常见的白血病，占所有白血病诊断的 38%。慢性淋巴细胞白血病新病例的年发病率为每 100,000 名男性和女性 4.9 例。因此，美国国家卫生联合会已授予赠款和研究金，以支持创新研究，以寻找更好的治疗方法和治愈多种出血性疾病的方法。这些研究为改善因子替代疗法以及更精确的慢性淋巴细胞白血病治疗带来了重要的见解，因此可以说增加了我们对该疾病遗传基础的理解。因此，这种疾病的流行率不断上升，以及一些组织越来越多的举措正在推动该地区的市场增长。

此外，美国监管部门批准的增加以及主要参与者的持续研究活动可能会在该地区贡献最大的收入份额，并推动全球慢性淋巴细胞白血病市场。 .例如，2019 年 11 月，阿斯利康 (AstraZeneca) PLC 获得美国食品药品监督管理局 (FDA) 批准 Calquence (acalabrutinib) 用于治疗成年 CLL 患者，推动全球慢性淋巴细胞白血病市场的增长。此外，一些主要参与者已建立合作伙伴关係，以开发市场并提高其在全球的地位。因此，政府计划增加对新生儿进行早期筛查的宣传活动和宣传活动预计将推动该地区的慢性淋巴细胞白血病药物市场。

竞争格局

慢性淋巴细胞白血病药物市场的主要参与者是、GlaxoSmithKline Plc、AbbVie Inc、Biogen Idec、AstraZeneca、Genentech Inc、MorphoSys AG、F. Hoffmann-La Roche AG、Teva Pharmaceutical Industries Ltd、Portola Pharmaceuticals、Inc、Celgene Corporation、MorboSys AG、AbbVie、Celgene Corporation、MorphoSys AG、AbbVie、Asta Zeneca、Celgene Corporation等等。

MorphoSys AG。

概述

MorphoSys AG 是一家总部位于德国慕尼黑附近的生物製药公司。在美国马萨诸塞州波士顿拥有全资子公司 MorphoSys US Inc.。该公司拥有广泛的抗体、蛋白质和□技术，并发现和开发自己的和合作的候选药物。该公司在其广泛的管道中拥有 100 多种针对各种疾病的药物正在研究中。此外，我们还有专注于癌症和自身免疫性疾病的管道。该公司与製药和生物技术公司合作开发药物。

产品组合

Monjubi (R) (tafasitamab-cxix)。 CD19 抗原在早期 B 淋巴细胞和 B 细胞淋巴瘤上表达，有望成为非霍奇金淋巴瘤如瀰漫性大 B 细胞淋巴瘤和慢性淋巴细胞白血病 (CLL) 的治疗靶点。

全球慢性淋巴细胞白血病药物市场报告提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 第 3 章：按癌症类型划分的市场细分
  • 按药物类型划分的市场细分
  • 按管理途径划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • CLL（慢性淋巴细胞白血病）的高患病率
      • 技术进步
    • 限制因素
      • 治疗费用高
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 监管分析
  • 专利分析

第6章流行病学分析

第 7 章管道分析

  • 管道概览
  • 主管道产品简介

第 8 章按癌症类型

  • B细胞慢性淋巴细胞白血病
  • T细胞慢性淋巴细胞白血病
  • 自然杀伤慢性淋巴细胞白血病

第 9 章按药物类型

  • 化疗药物
  • 免疫学/靶向药物
    • 维奈托克
    • 依鲁替尼
    • 奥比妥珠单抗
    • 优雅的
    • 其他

第 10 章按给药途径

  • 静脉途径
  • 口服给药途径
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 竞争性慢性淋巴细胞白血病药物的策略分析
  • 比较产品组合分析
  • 市场情况/份额分析
  • 併购分析

第 13 章公司简介

  • 葛兰素史克公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • AbbVie Inc.
  • Biogen Idec
  • AstraZeneca
  • Genentech Inc.
  • MorphoSys AG
  • F. Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries Ltd.
  • Portola Pharmaceuticals, Inc
  • Celgene Corporation

第14章 重要考察

第15章 DataM

简介目录
Product Code: DMPH1792

Market Overview

Chronic Lymphocytic Leukemia Therapeutics Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.90% during the forecast period (2022-2029).

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes involved in producing antibodies to fight against infections and foreign antigens. Chronic lymphocytic leukemia symptoms include swollen lymph nodes, fever, exhaustion, abdominal pain from an enlarged spleen, weight loss, night sweats, repeated infections, and others.

Market Dynamics

Increasing FDA approvals for treating Chronic Lymphocytic Leukemia is expected to drive market growth.

The Food and Drug Administration (FDA) of the United States authorized Imbruvica (ibrutinib) in conjunction with rituximab on April 21, 2020, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This is the 11th FDA approval for Imbruvica (ibrutinib) since it was approved in 2013 and the sixth in CLL, the most common form of adult leukemia. Moreover, On November 9, 2020, the European Medical Agency (EMA), the European Union for treating adult patients with chronic lymphocytic leukemia (CLL). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Stringent government regulations, inadequate reimbursement policies in emerging countries, and multiple patent expiration are the factors the market is expected to hamper the market growth.

Industry Analysis

The chronic lymphocytic leukemia therapeutics market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis, epidemiology etc.

Segment Analysis

Targeted Therapy segment is expected to hold the largest market share in the chronic lymphocytic leukemia therapeutics market.

The targeted therapy segment accounted for the largest market share in 2021. Targeted therapies are drugs that specifically target the changes inside cells that cause them to become cancer. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells in general (including cancer cells), these drugs target one or more specific proteins on or in chronic lymphocytic leukemia (CLL) cells. When treatment is needed for CLL, a targeted drug is often part of the first line of treatment. Targeted therapies use information about a person's genes and protein to prevent, diagnose, and treat disease, making them extremely applicable in precision medicine. Targeted therapy drugs are mainly used for cancer treatment, along with other treatments such as chemotherapy, surgery, and radiation therapy. The targeted cancer therapies market is growing due to the increasing incidences of chronic lymphocytic leukemia (CLL). For instance, according to the report published by the American Cancer Society in January 2020, the risk of CLL increases with age, and it estimates that about 9 out of 10 people with CLL are over age 50, directly driving for growth of the CLL market. The major types of targeted drugs most commonly used to treat CLL include Rituximab (Rituxan), Ofatumumab (Arzerra), Obinutuzumab (Gazyva), Venetoclax (Venclexta), Ibrutinib (Imbruvica) and Idelalisib (Zydelig). Therefore, it has increased the demand for targeted therapy. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global chronic lymphocytic leukemia therapeutics market.

North America accounted for the largest market share in 2021. The rising incidence of CLL coupled with a high mortality rate demonstrates the unmet market need for better therapeutics. For instance, according to cancer.net, in 2021, 21,250 people of all ages (13,040 men and boys and 8,210 women and girls) in the United States will be diagnosed with CLL. While it can occur at any age, CLL is more common in older adults. The average age at diagnosis is around 70. CLL is uncommon in people younger than 40 and is very rare in children. CLL is the most common type of leukemia in adults older than 19, accounting for 38% of all leukemia diagnoses. The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year. Therefore, National Health Federation in the United States has been awarding grants and fellowships to support innovative research to find better treatments and cures for several bleeding disorders. Such research has led to vital insights into improved factor replacement therapies, along with more accurate chronic lymphocytic leukemia therapeutics methods and, therefore, definitely a greater understanding of the genetic basis of the disease. Hence, the rising prevalence of the disease and the growing initiatives by several organizations are driving market growth in the region.

Moreover, an increase in the approvals from regulatory bodies and ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region, propelling the global chronic lymphocytic leukemia market. For instance, in November 2019, AstraZeneca PLC received US Food and Drug Administration (FDA) approval for its Calquence (acalabrutinib) to treat adult patients with CLL, which is expected to impel the global Chronic lymphocytic leukemia market growth. Furthermore, few key players are entering into partnerships to develop and increase their market position globally. Thus, rising awareness campaigns and supportive initiatives planned by the government to commence early screening of neonates are expected to boost the market for chronic lymphocytic leukemia therapeutics in the region.

Competitive Landscape

Major key players in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline Plc, AbbVie Inc., Biogen Idec, AstraZeneca, Genentech Inc., MorphoSys AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Portola Pharmaceuticals, Inc, Celgene Corporation.

MorphoSys AG:

Overview:

MorphoSys AG is a biopharmaceutical company headquartered near Munich, Germany. The company has a wholly-owned subsidiary, MorphoSys US Inc., in Boston, MA, in the US. The company has various antibody, protein and peptide technologies to discover and develop proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are investigated for various diseases. Moreover, the company also has a pipeline focusing on cancer and autoimmune diseases. The company develops its drugs in partnership with pharma and biotech companies.

Product Portfolio:

Monjuvi(R)(tafasitamab-cxix): It is also known as MOR208, is a humanized monoclonal antibody precision medicine directed against the CD19 antigen, which is expressed on early B lymphocytes and B cell lymphomas which makes it a potential target for the treatment of non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma, as well as chronic lymphocytic leukemia (CLL).

The global chronic lymphocytic leukemia therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market Snippet by Drug Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High Prevalence of CLL(Chronic Lymphocytic Leukemia)
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Patent Analysis

6. Epidemiology Analysis

7. Pipeline Analysis

  • 7.1. Pipeline Overview
  • 7.2. Key Pipeline Product Profiles

8. By Cancer Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.1.2. Market Attractiveness Index, By Cancer Type
  • 8.2. B-cell chronic lymphocytic leukemia
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 8.3. T-cell chronic lymphocytic leukemia
  • 8.4. Natural killer chronic lymphocytic leukemia.

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Chemotherapy Drugs
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 9.3. Immuno and Targeted Drugs
    • 9.3.1. Venetoclax
    • 9.3.2. Ibrutinib
    • 9.3.3. Obinutuzumab
    • 9.3.4. Duvelisib
    • 9.3.5. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Intravenous route
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
  • 10.3. Oral Route
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. The U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. The U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East & Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Competitor Chronic Lymphocytic Leukemia Therapeutics Strategy Analysis
  • 12.3. Comparative Product Portfolio Analysis
  • 12.4. Market Positioning/Share Analysis
  • 12.5. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. GlaxoSmithKline Plc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AbbVie Inc.
  • 13.3. Biogen Idec
  • 13.4. AstraZeneca
  • 13.5. Genentech Inc.
  • 13.6. MorphoSys AG
  • 13.7. F. Hoffmann-La Roche AG
  • 13.8. Teva Pharmaceutical Industries Ltd.
  • 13.9. Portola Pharmaceuticals, Inc
  • 13.10. Celgene Corporation

14. Premium Insights

15. DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us